CORONA

CORONA Remedies Limited

Source: NSE · Updated 4 Nov, 11:32 pm IST

Filed 30 Oct, 06:54 pm IST Q2 FY27 (Sep ’26)Consolidated₹ crores

Revenue

441.17

▲ 22.2% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

95.95

▲ 22.3% vs Q2 FY26

Net profit

60.31

▲ 15.3% vs Q2 FY26

EPS (₹)

9.86

▲ 15.3% vs Q2 FY26

Operating margin

21.7%

+0 bps vs Q2 FY26

Net margin

13.7%

−80 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+22% vs Q2 FY26 · +4% vs Q1 FY27

Profit+15% vs Q2 FY26 · ±0% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	441.17	422.43	▲ 4.4%	361.13	▲ 22.2%
Other income	2.48	3.15	▼ 21.3%	2.27	▲ 9.3%
Total income	443.65	425.58	▲ 4.2%	363.4	▲ 22.1%
Total expenses	363.03	345.23	▲ 5.2%	293.79	▲ 23.6%
Operating profit (EBITDA)*	95.95	93.13	▲ 3.0%	78.47	▲ 22.3%
Profit before tax	80.62	80.35	▲ 0.3%	69.61	▲ 15.8%
Tax expense	20.44	20.25	▲ 0.9%	17.46	▲ 17.1%
Net profit	60.31	60.11	▲ 0.3%	52.32	▲ 15.3%
EPS (₹)	9.86	9.83	▲ 0.3%	8.55	▲ 15.3%
Operating margin	21.7%	22.0%	−30 bps	21.7%	+0 bps
Net margin	13.7%	14.2%	−50 bps	14.5%	−80 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ crores except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All CORONA Remedies results, dividends & filings ›

Other results filed 30 Oct

POLICYBZR PB Fintech Limited›GMRP&UI GMR Power and Urban Infra Limited›IOLCP IOL Chemicals and Pharmaceuticals Limited›SHAREINDIA Share India Securities Limited›FINPIPE Finolex Industries Limited›LCCPROJECT LCC Projects Limited›TI Tilaknagar Industries Limited›IRMENERGY IRM Energy Limited›QUESS Quess Corp Limited›RELIANCE Reliance Industries Limited›ZEEL Zee Entertainment Enterprises Limited›CHEMBOND Chembond Material Technologies Limited›

Today's results ›

CORONA REMEDIES Q2 FY27 ; NET PROFIT UP 15% AT ₹60 CR (YOY), UP 0% (QOQ)

REVENUE UP 22% AT ₹441 CR (YOY), UP 4% (QOQ)

EBITDA UP 22% AT ₹96 CR (YOY), UP 3% (QOQ)

MARGINS AT 21.7% VS 21.7% (YOY), 22.0% (QOQ)

https://resultkal.com/r/corona-2026-10-30
Source: NSE filing · not investment advice

FAQ

When did CORONA Remedies announce Q2 FY27 results?

CORONA Remedies filed its results on NSE on 30 Oct, 06:54 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these CORONA Remedies figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← CORONA overview